By Colin Kellaher

Celgene Corp. (CELG) on Friday said it submitted a biologics-license application with the U.S. Food and Drug Administration for luspatercept, an anemia drug it is developing with Acceleron Pharma Inc. (XLRN).

The Summit, N.J., biopharmaceutical company said the filing covers treatment of adults with anemia related to very low to intermediate risk myelodysplastic syndromes with ring sideroblasts who require red blood cell transfusions, as well as adults with anemia related to beta-thalassemia-associated anemia who require red blood cell transfusions.

Celgene and Acceleron, based in Cambridge, Mass., said they plan to submit a luspatercept marketing application to the European Medicines Agency during the second quarter.

The companies formed their development and commercialization collaboration in 2011.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 05, 2019 10:09 ET (14:09 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024 Haga Click aquí para más Gráficas Acceleron Pharma.
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024 Haga Click aquí para más Gráficas Acceleron Pharma.